🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

162 results for “Fondazione” Clear

  1. OPDIVO 10 mg/mL concentrate for solution for infusion., FLUOROURACIL , Oxaliplatino Sandoz, LEDERFOLIN 175 mg polvere per soluzione per infusione, FLUOROURACIL , SIMVASTATIN, CAPECITABINE

    Fondazione Telethon ETS

    advanced or metastatic gastrooesophageal carcinoma HER2 negative and ARID1A mutated

    phase 2 small molecule active

    1 trial

  2. Ocrevus 300 mg concentrate for solution for infusion, CYTARABINE, CARMUSTINE, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE, Tysabri 300 mg concentrate for solution for infusion, CARMUSTINE, ETOPOSIDE, CARMUSTINE, UBLITUXIMAB, MELPHALAN FLUFENAMIDE, FILGRASTIM, FILGRASTIM, CYTARABINE, CYTARABINE, CYCLOPHOSPHAMIDE, RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, Kesimpta 20 mg solution for injection in pre-filled pen, ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS, CYTARABINE, LEMTRADA 12 mg concentrate for solution f

    Fondazione Telethon ETS

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  3. Odomzo 200 mg hard capsules

    Fondazione Telethon ETS

    locally advanced basal cell carcinoma

    phase 2 small molecule active

    1 trial

  4. Orgovyx 120 mg film-coated tablets

    Fondazione Telethon ETS

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  5. PACLITAXEL ALBUMIN-BOUND, NIVOLUMAB, CISPLATIN

    Fondazione Telethon ETS

    Patients with non-metastatic muscle invasive bladder cancer

    phase 2 small molecule active

    1 trial

  6. PEMBROLIZUMAB, ATEZOLIZUMAB, NIVOLUMAB, CEMIPLIMAB

    Fondazione Telethon ETS

    Unresectable or metastatic melanoma, Locally advanced or metastatic urothelial carcinoma, Locally advanced or metastatic non-small cell lung cancer (NSCLC), Untreated recurrent/metastatic head & neck sqamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  7. PIRTOBRUTINIB

    Fondazione Telethon ETS

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  8. PONATINIB, CYCLOPHOSPHAMIDE, VINCRISTINE, BESPONSA 1 mg powder for concentrate for solution for infusion, METHOTREXATE, PURINETHOL 50 mg compresse, PREDNISONE

    Fondazione Telethon ETS

    Acute B-cell Lymphoblastic Leukemia with minimal residual positive disease prior to haematopoietic stem cell transplantation in adult patients

    phase 2 small molecule active

    1 trial

  9. PTG-CARCIK-CD19

    Fondazione Telethon ETS

    B-Non Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  10. PTG-CARCIK-CD19

    Fondazione Telethon ETS

    B cell precursor Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  11. Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Tislelizumab, Paclitaxel 6 mg/mL concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion

    Fondazione Telethon ETS

    Resectable Locally Advanced Oral Cavity Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  12. Pemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione, JNJ-61186372

    Fondazione Telethon ETS

    Non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  13. Phase 1b/2 trial of 5-fluorouracil, leucovorin, irinotecan in combination with temozolomide (FLIRT) and bevacizumab for the first-line treatment of patients with MGMT silenced, microsatellite stable metastatic colorectal cancer.

    Fondazione Telethon ETS

    metastatic colorectal cancer

    phase 2 other active

    1 trial

  14. Placebo vials contain 4.5 ml of storage solution only (2.5 ml albumin 20%, 1.1 ml normal saline solution, 0.45 ml Citrate dextrose solution, 0.45 ml Dimethyl sulfoxide). Placebo and MSC vials are indistinguishable in appearance after thawing. There are no observable differences between treatments that could potentially compromise the blind., Mesenchymal stromal cells

    Fondazione Telethon ETS

    Traumatic Brain Injury

    phase 2 small molecule active

    1 trial

  15. RELUGOLIX

    Fondazione Telethon ETS

    Intermediate risk prostate cancer

    phase 2 small molecule active

    1 trial

  16. RITUXIMAB , DOXORUBICIN , VINCRISTINE , IBRUTINIB , RITUXIMAB, PREDNISONE , CYCLOPHOSPHAMIDE

    Fondazione Telethon ETS

    Diffuse Large B-cell Lymphoma ABC

    phase 2 small molecule active

    1 trial

  17. RITUXIMAB, Golcadomide

    Fondazione Telethon ETS

    Diffuse Large B-cells non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  18. Rabipur Polvere e solvente per soluzione iniettabile in siringa preriempita. Vaccino rabico (inattivato)., TICOVAC 0,25 ml per uso pediatrico Sospensione iniettabile in una siringa preriempita Vaccino (virus intero, inattivato) contro l'encefalite da zecca, AUTOLOGOUS PERIPHERAL BLOOD-DERIVED CD4+ T-CELLS CRISPR-EDITED AT THE CD40LG LOCUS, Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomye

    Fondazione Telethon ETS

    X-linked immunodeficiency with hyper-IgM type 1 (HIGM1)

    phase 2 small molecule active

    1 trial

  19. Romidepsin

    Fondazione Telethon ETS

    Anaplastic Large T-cell Lymphoma ALK negative, Angioimmunoblastic T-cell Lymphoma, Peripheral T-cell lymphoma, NOS

    phase 2 small molecule active

    1 trial

  20. Rubraca 300 mg film-coated tablets, Rubraca 200 mg film-coated tablets, BEVACIZUMAB, Rubraca 250 mg film-coated tablets, CARBOPLATIN, PACLITAXEL

    Fondazione Telethon ETS

    Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer.

    phase 2 small molecule active

    1 trial

  21. SILIMARIN 200 mg compresse rivestite, Kisqali 200 mg film-coated tablets

    Fondazione Telethon ETS

    hormone receptor positive, HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  22. SOLDESAM 0,2% gocce orali, soluzione, DARZALEX 1800 mg solution for injection, Imnovid 3 mg hard capsules, SOLDESAM 8 mg/2 ml soluzione iniettabile, Imnovid 4 mg hard capsules, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules

    Fondazione Telethon ETS

    Multiple Myeloma relapsed and/or refractory

    phase 2 small molecule active

    1 trial

  23. SOLDESAM 0,2% gocce orali, soluzione, Pepaxti 20 mg powder for concentrate for solution for infusion, SOLDESAM 8 mg/2 ml soluzione iniettabile

    Fondazione Telethon ETS

    Relapsed Multiple Myeloma

    phase 2 small molecule active

    1 trial

  24. Sodio Cloruro DIACO 0,9% Soluzione per infusione, Prolastin 1000 mg, polvere e solvente per soluzione per infusione

    Fondazione Telethon ETS

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources